Search by Drug Name or NDC
NDC 62135-0706-37 lamivudine 10 mg/mL Details
lamivudine 10 mg/mL
lamivudine is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Chartwell RX, LLC. The primary component is LAMIVUDINE.
MedlinePlus Drug Summary
Lamivudine (Epivir) is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 3 months of age and older. Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. Although lamivudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV or hepatitis B virus to other people.
Related Packages: 62135-0706-37Last Updated: 04/28/2024
MedLinePlus Full Drug Details: Lamivudine
Product Information
| NDC | 62135-0706 |
|---|---|
| Product ID | 62135-706_0155ccec-81e2-8900-e063-6294a90afacd |
| Associated GPIs | |
| GCN Sequence Number | 024418 |
| GCN Sequence Number Description | lamivudine SOLUTION 10 MG/ML ORAL |
| HIC3 | W5J |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NUCLEOSIDE ANALOG, RTI |
| GCN | 26722 |
| HICL Sequence Number | 010215 |
| HICL Sequence Number Description | LAMIVUDINE |
| Brand/Generic | Generic |
| Proprietary Name | lamivudine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | lamivudine oral |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 10 |
| Active Ingredient Units | mg/mL |
| Substance Name | LAMIVUDINE |
| Labeler Name | Chartwell RX, LLC |
| Pharmaceutical Class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA203564 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 62135-0706-37 (62135070637)
| NDC Package Code | 62135-706-37 |
|---|---|
| Billing NDC | 62135070637 |
| Package | 240 mL in 1 BOTTLE, PLASTIC (62135-706-37) |
| Marketing Start Date | 2023-07-20 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |